Food and Drug Administration (FDA)

letters

POGO Asks President to Withdraw FDA Nominee POGO Urges Senate to Vote Against Nominee to the FDA POGO Letter to Associate Commissioner Warner, FDA, Questioning FDA's Handling of Conflicts of Interest on FDA Advisory Committees POGO and Partners Oppose House Bill that Allows FDA More Secrecy POGO and Groups Support Better Information on Clinical Trials POGO and Partners Oppose FDA Secrecy POGO Letter: FDA Advisors on Yaz and Yasmin Have Industry Ties POGO Letter Urges FDA Not to Weaken Conflict of Interest Standards at Center for Drug Evaluation and Research POGO Letter to FDA Commissioner Hamburg Concerning the Potentially Dangerous Interaction of the Drugs Seroquel and Methodone POGO Asks DHHS Secretary Sebelius to Reinvestigate FDA's Negligent Oversight of Unsafe Medical Devices POGO Letter to FDA Commissioner Margaret Hamburg Regarding Potentially Dangerous Drug Interaction Invovling Seroquel and Methadone POGO's letter to Deputy HHS IG on FDA's CDRH's low standard of medical devices approval The Finances Of FDA Advisory Committee Members: If Information Must Be Withheld, Let It Be Done Openly POGO's letter to Commissioner Hamburg regarding medical devices POGO Letter to FDA's Daniel Schultz MD regarding a policy decision by CDRH to discontinue inspections of nonclinical laboratories POGO Asks FDA Head to Have Deadly Syringe Incident Investigated POGO letter to FDA's Daniel Schultz MD regarding the lack of GLP inspections POGO Follow-up letter to CDRH Director Daniel Schultz POGO Letter to CDRH Director Daniel Schultz regarding a series of questions about the apparent decision not to enforce the GLP regulation

Latest

Jack Mitchell: Public Interest Warrior

analysis | December 10, 2019 | Danielle Brian & Keith Rutter

Read

Latest

Paper Cuts: Slow Stroll to Salad Safety

analysis | June 13, 2018 | Bonnie Goldstein

Read

Patient Advocates Get Big Funding from Big Pharma

analysis | June 7, 2018 | Rebecca Jones
Unrigging the System

analysis | February 2, 2018 | Emma Stodder
Biotech Exec Hosted by Trump Butters Up FDA Chief

analysis | December 14, 2017 | David S. Hilzenrath
IG Calls for Detailed Reporting on Medical Device Failures

analysis | October 10, 2017 | CJ Ostrosky & Nick Schwellenbach
Congress, FDA Poised to Loosen Oversight of Medical Devices

investigation | June 20, 2017 | David S. Hilzenrath
2017 Baker’s Dozen of Suggested Congressional Oversight Priorities and Legislative Reforms

report | March 28, 2017 | Liz Hempowicz
Trump’s Dangerous Prescription for the FDA

investigation | March 3, 2017 | David S. Hilzenrath
FDA Set Low Bar for Approval of Blood Thinners

analysis | December 12, 2016 | David S. Hilzenrath